Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Mather Group LLC.

Mather Group LLC. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,015 shares of the pharmaceutical company’s stock after buying an additional 80 shares during the quarter. Mather Group LLC.’s holdings in Vertex Pharmaceuticals were worth $1,867,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. University of Texas Texas AM Investment Managment Co. purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at about $25,000. Annapolis Financial Services LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter worth approximately $27,000. GHP Investment Advisors Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth approximately $29,000. Stephens Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $31,000. Finally, Founders Capital Management boosted its holdings in Vertex Pharmaceuticals by 50.0% in the second quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the transaction, the director now directly owns 4,435 shares in the company, valued at approximately $2,217,500. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the completion of the sale, the chief executive officer now directly owns 106,172 shares in the company, valued at $52,767,484. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,487 shares of company stock worth $14,657,149 over the last 90 days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $458.94 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. The stock has a market capitalization of $118.45 billion, a price-to-earnings ratio of 29.77 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a one year low of $341.90 and a one year high of $510.64. The company’s 50-day simple moving average is $475.76 and its 200-day simple moving average is $456.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. Vertex Pharmaceuticals’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.53 EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of research reports. Guggenheim raised their price objective on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Truist Financial reiterated a “buy” rating and set a $550.00 price objective (up from $508.00) on shares of Vertex Pharmaceuticals in a research note on Monday, August 5th. Barclays downgraded shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $472.00 to $509.00 in a research note on Monday, August 5th. Oppenheimer upped their price target on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Hold” and an average price target of $486.95.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.